Filing excerpt
Otarmeni (lunsotogene parvec, formerly known as DB-OTO) AAV-based gene therapy Hearing loss due to variants of otoferlin ("OTOF") gene(c)(e)(m) (Phase 1/2) (pivotal study) Approved by FDA for hearing loss associated with variants in OTOF gene